Clinical trials: sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.
Non Small Cell Lung Cancer
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
This study is an open, multicenter, phase 2 clinical trial of SPGL008 in combination with SSGJ-706 ± chemotherapy for the treatment of advanced non-small cell lung cancer.
- Trial name
- NCT07874984
- Testing
- SSGJ-706, SPGL008, Chemotherapy
- Volunteers
- 220 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Metastatic Breast Cancer
A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
This study is a phase II clinical trial of SSGJ-612 combined with a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) in patients with hormone receptor (HR)-positive, HER2-low or HER2-ultralow…
- Trial name
- NCT07757230
- Testing
- SSGJ-612 (HER2-targeted antibody), HER2-targeted ADC
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Advanced Solid Tumors Patients
Phase I Clinical Study to Evaluate the Safety and Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors
This study includes two parts, different part has different administration frequencies of 3SC009.
- Trial name
- NCT07815002
- Testing
- 3SC009
- Volunteers
- 100 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Locally Advanced (Unresectable) or Metastatic Solid Tumors
SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.
- Trial name
- NCT07646626
- Testing
- SSGJ-705, SSGJ-612, SSGJ-705 combined with chemotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Healthy
A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants
This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK, PD and immunogenicity of SSS68 in healthy adult participants following a single…
- Trial name
- NCT07606976
- Testing
- SSS68
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Healthy
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion
This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK, preliminary PD and immunogenicity of SSS67 in healthy adult participants after single…
- Trial name
- NCT07487545
- Testing
- SSS67 Injection
- Where
- 2 sites in Australia, China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
NMIBC
The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.
The goal of clinical trial is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With on-Muscle-Invasive Bladder Cancer. The main questions it aims to answer are: 1.
- Trial name
- NCT07445308
- Testing
- SPGL008
- Volunteers
- 120 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Safety Issues
Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects
This study was a single-dose, randomized, double-blind, placebo-controlled study of SSS55 injection to evaluate the safety, tolerability, PK characteristics, immunogenicity and preliminary efficacy characteristics of single-dose…
- Trial name
- NCT07058779
- Testing
- SSS55
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Advanced Malignant Tumors
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.
- Trial name
- NCT07038005
- Testing
- SPGL008
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Advanced Malignant Tumors
A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors
This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.
- Trial name
- NCT07016490
- Testing
- SSGJ-709
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
First-line Advanced NSCLC Patients
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC
- Trial name
- NCT07171606
- Testing
- SSGJ-706, pemetrexed /carboplatin, Carboplatin/Paclitaxel
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors.
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer
- Trial name
- NCT07233850
- Testing
- SSGJ-706+XELOX, SSGJ-706+Bevacizumab+XELOX, SSGJ-706+AG
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Locally Advanced, Recurrent or Metastatic Malignancies
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
- Trial name
- NCT07022002
- Testing
- SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Advanced Malignant Tumors
A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors
This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.
- Trial name
- NCT07032298
- Testing
- SSGJ-612
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Advanced Solid Tumors
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.
- Trial name
- NCT06993870
- Testing
- HBT-708
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Safety and Tolerability in Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects
To evaluate the safety, tolerability, and pharmacokinetics of SSS39 injection in healthy Chinese subjects
- Trial name
- NCT07057726
- Testing
- SSS39
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Healthy Subjects (HS)
A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males
This study aims to evaluate the absorption, metabolism, and excretion of a single oral dose of [¹⁴C]SSS17 in healthy adult Chinese male subjects, elucidating its overall pharmacokinetic profile in humans to provide essential…
- Trial name
- NCT07025915
- Testing
- [14C]SSS17
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Advanced Non-Small Cell Lung Cancer
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT06980272
- Testing
- SSGJ-707, Pembrolizumab
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Anemia in Pre-Dialysis Patients
Phase II Dose-Finding of Oral SSS17 for Anemia in Non-Dialysis CKD
This study primarily evaluates the efficacy and safety of oral SSS17 capsules in treating anemia in patients with non-dialysis chronic kidney disease, as well as the pharmacokinetic and pharmacodynamic (PK/PD) characteristics of…
- Trial name
- NCT07014631
- Testing
- SSS17
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Healthy Subjects (HS)
A Study Evaluating the Food Effect on the Pharmacokinetics of SSS17 Capsules in Chinese Healthy Subjects
This study mainly compared the blood drug concentration and main pharmacokinetic parameters of SSS17 capsules taken orally once by healthy Chinese subjects under fasting conditions, 2 hours after administration, and when…
- Trial name
- NCT07024888
- Testing
- SSS17
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.